文献速递重症综合管理与镇静镇痛复苏、休克与脓毒症

脓毒症患者的血小板下降与纤溶关闭

Platelet Drop and Fibrinolytic Shutdown in Patients With Sepsis.
PubMed 文献 · Crit Care Med · 2018-01-01
一句话结论严重脓毒症中纤溶抑制(纤溶酶原激活物抑制剂1升高、凝血酶激活的纤溶抑制物活化)是早期表现,可先于血小板减少出现;凝血酶激活的纤溶抑制物水平是死亡的独立预测因素。

本研究为意大利40个ICU、源自白蛋白替代治疗严重脓毒症或脓毒症休克的多中心随机对照试验(Albumin Italian Outcome Sepsis trial)的巢式研究。按血小板计数分为三组:入组时血小板≤50×10^9/L者85例、基线血小板≥100×10^9/L但28天内降至≤50×10^9/L者100例、血小板始终≥100×10^9/L者95例,第1天检测纤溶指标。早期血小板减少组与后期发生血小板减少组病情严重度和90天死亡率相似,而无血小板减少组病情较轻、死亡率较低;前两组纤溶均显著且相似地受抑。校正简化急性生理评分-II、性别和血小板计数后,仅凝血酶激活的纤溶抑制物水平及纤溶激活的体内标志物(纤溶酶-抗纤溶酶复合物、D-二聚体)与死亡率独立相关;纤溶受损合并低血小板者死亡率更高。

要点

  • 严重脓毒症第1天即可见纤溶显著受抑,主要表现为纤溶酶原激活物抑制剂1升高和凝血酶激活的纤溶抑制物广泛活化/消耗,且该改变可先于血小板减少出现。
  • 早期血小板减少(入组时≤50×10^9/L,85例)与后期发生血小板减少(基线≥100×10^9/L、28天内≤50×10^9/L,100例)者病情严重度和90天死亡率相似,均重于血小板始终≥100×10^9/L者(95例)。
  • 校正简化急性生理评分-II、性别和血小板计数后,仅凝血酶激活的纤溶抑制物水平、纤溶酶-抗纤溶酶复合物和D-二聚体与死亡率独立相关。
  • 纤溶受损与低血小板并存时死亡率更高,提示两者联合可用于严重脓毒症的风险分层。
  • 多数纤溶变量仅在单变量模型中与死亡率相关,多变量校正后不再独立。

适用人群与场景

  • 意大利40个ICU中严重脓毒症或脓毒症休克患者,选自白蛋白替代治疗的多中心随机对照试验(Albumin Italian Outcome Sepsis trial)的巢式研究。
  • 第1组:研究入组时血小板计数≤50×10^9/L(n=85);第2组:基线血小板计数≥100×10^9/L、28天内发生血小板减少(≤50×10^9/L)(n=100);第3组:血小板计数始终≥100×10^9/L(n=95)。

诊断标准与关键阈值

  • 血小板减少定义采用血小板计数≤50×10^9/L;血小板正常参照为≥100×10^9/L。
  • 纤溶指标于第1天检测,包括纤溶抑制物和纤溶酶生成的体内标志物。

红旗征与不能漏的情况

  • 纤溶受损与低血小板并存时死亡率更高,提示该类严重脓毒症患者风险更高。

研究设计与关键结果

  • 研究类型:多中心随机对照试验(Albumin Italian Outcome Sepsis trial)的巢式研究,40个ICU,共纳入三组患者:入组时血小板≤50×10^9/L者85例、基线≥100×10^9/L但28天内降至≤50×10^9/L者100例、始终≥100×10^9/L者95例。
  • 早期血小板减少组与后期发生血小板减少组病情严重度和90天死亡率相似,无血小板减少组病情较轻、死亡率较低。
  • 与无血小板减少组相比,早期和后期血小板减少两组纤溶均显著且相似地受抑,主要改变为纤溶酶原激活物抑制剂1水平升高及凝血酶激活的纤溶抑制物广泛活化/消耗。
  • 多数纤溶变量在单变量模型中与死亡率显著相关;校正简化急性生理评分-II评分、性别和血小板计数后,仅凝血酶激活的纤溶抑制物水平、纤溶酶-抗纤溶酶复合物和D-二聚体与死亡率独立相关。
  • 纤溶受损与低血小板并存与更高的死亡率相关。

证据类型、等级与局限

  • 证据类型:源自多中心随机对照试验的巢式研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,纤溶受损(主要由纤溶酶原激活物抑制剂1升高和凝血酶激活的纤溶抑制物活化驱动)是脓毒症的早期表现,可能先于血小板减少出现。
  • 作者认为,凝血酶激活的纤溶抑制物水平是死亡的独立预测因素,可能改善严重脓毒症患者的风险分层。
  • 原文未据此给出治疗推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: Thrombocytopenia is the most common hemostatic disorder during sepsis and is associated with high mortality. We examined whether fibrinolytic changes precede incident thrombocytopenia and predict outcome in patients with severe sepsis.

DESIGN: Nested study from the multicenter, randomized, controlled trial on the efficacy of albumin replacement in severe sepsis or septic shock (the Albumin Italian Outcome Sepsis trial).

SETTING: Forty ICUs in Italy.

PATIENTS: Three groups of patients were selected: 1) patients with platelet count less than or equal to 50 × 10/L at study entry (n = 85); 2) patients with baseline platelet count greater than or equal to 100 × 10/L who developed thrombocytopenia (≤ 50 × 10/L) within 28 days (n = 100); 3) patients with platelet count always more than or equal to 100 × 10/L (n = 95).

INTERVENTIONS: Fibrinolytic variables, including fibrinolysis inhibitors and in vivo markers of plasmin generation, were measured on day 1.

MEASUREMENTS AND MAIN RESULTS: Patients with early thrombocytopenia (group 1) and those who developed it later (group 2) had similar illness severity and 90-day mortality, whereas patients without thrombocytopenia (group 3) had milder disease and lower mortality. Fibrinolysis was markedly (and similarly) depressed in groups 1 and 2 as compared with group 3. Major fibrinolytic changes included increased levels of plasminogen activator inhibitor 1 and extensive activation/consumption of thrombin activatable fibrinolysis inhibitor. Most fibrinolytic variables were significantly associated with mortality in univariate models. However, only thrombin activatable fibrinolysis inhibitor level and in vivo markers of fibrinolysis activation, namely plasmin-antiplasmin complex, and D-dimer, were independently associated with mortality after adjustment for Simplified Acute Physiology Score-II score, sex, and platelet count. Furthermore, the coexistence of impaired fibrinolysis and low platelets was associated with an even greater mortality.

CONCLUSIONS: Impaired fibrinolysis, mainly driven by plasminogen activator inhibitor-1 increase and thrombin activatable fibrinolysis inhibitor activation, is an early manifestation of sepsis and may precede the development of thrombocytopenia. Thrombin activatable fibrinolysis inhibitor level, in particular, proved to be an independent predictor of mortality, which may improve risk stratification of patients with severe sepsis.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Semeraro F, Colucci M, Caironi P, et al. Platelet Drop and Fibrinolytic Shutdown in Patients With Sepsis. Crit Care Med. 2018. PMID: 29261568. doi:10.1097/CCM.0000000000002919

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。